We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Panitumumab w leczeniu chorych na raka jelita grubego.
- Authors
Słowik, Agnieszka J.; Wysocki, Piotr
- Abstract
Panitumumab is a fully human monoclonal IgG2 antibody registered in the treatment of metastatic colorectal cancer (mCRC). Efficacy of this therapy is limited only to the group of patients with wild-type RAS status (non-mutated). As a result 2,3,4 exon of KRAS and NRAS gene testing remains gold standard before introducing panitumumab. Additionally, assessment of the BRAF mutation status is required (V600E mutation in the programme of National Health Fund; no adnotation in the Summary of Product Characteristics). Effectivness of the panitumumab was proven both in the first line of mCRC therapy and later in the course of treatment, after failure of standard chemotherapy with oxaliplatin, 5-fluorouracil and irinotecan. Toxicity is typical for the EGFR receptor blockers and does not limit the efficacy of the antibody. Panitumumab has a well established position in the mCRC therapy due to the positive influence on prognosis and presence of pedictive biomarkers enabling initial selection of patients potentilly responding to the treatment.
- Subjects
PANITUMUMAB; DRUG efficacy; GENETIC mutation; METASTASIS; GENETIC testing; COLORECTAL cancer; DRUG toxicity
- Publication
Gastroenterologia Kliniczna, 2022, Vol 14, Issue 4, p139
- ISSN
2081-1020
- Publication type
Article